Using Label-free Ultrasound Angio-Morphometry Analysis for Improving Ultrasound Specificity in Breast Cancer Detection and Treatment Monitoring

使用无标记超声血管形态测量分析提高乳腺癌检测和治疗监测中的超声特异性

• 批准号: 10183203
• 负责人: Azra Alizad
• 金额: $ 59.75万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10183203
• 关键词: 3-Dimensional; Address; Anxiety; Architecture; Area; Assessment tool; Benign; Biomedical Engineering; Biopsy; Blood Vessels; Breast; Breast Cancer Detection; Breast Cancer Patient; Breast biopsy; Characteristics; Clinic; Clinical; Clinical Assessment Tool; Clinical Research; Collaborations; Complement; Computer software; Contrast Media; Data; Detection; Development; Diagnostic; Disease Progression; Distant Metastasis; Environment; Evaluation; Goals; Gold; Growth; Image; Imaging technology; Label; Lead; Magnetic Resonance Imaging; Malignant - descriptor; Malignant Neoplasms; Mammography; Mass in breast; Methods; Modification; Monitor; Morbidity - disease rate; Morphology; Pathology; Patients; Performance; Population; Price; Procedures; Research; Specificity; Techniques; Technology; Three-Dimensional Imaging; Translating; Trauma; Ultrasonography; Uncertainty; United States; Vision; Visualization; Woman; angiogenesis; anticancer research; base; breast cancer diagnosis; breast imaging; breast lesion; cancer care; cancer therapy; chemotherapy; clinical practice; cost; density; efficacy evaluation; experience; high resolution imaging; imaging biomarker; imaging modality; imaging system; improved; innovation; malignant breast neoplasm; morphometry; mortality; new technology; novel; patient oriented; patient population; portability; predicting response; prognostic; quantitative imaging; research facility; response; tool; treatment response; tumor

SUMMARY Pre-biopsy evaluation of breast masses is a very critical step in selecting the right group to be biopsied. Current imaging methods, e.g., mammography and ultrasound (US), carry low specificity rates that lead to a great number of unnecessary biopsies. In the United States, the cost of potentially unwarranted biopsies is more than $3 billion annually and associated with significant trauma and anxiety for the patients due to this invasive procedure. Another area of uncertainty is assessing response to preoperative chemotherapy, where MRI has limitation due to high price and inaccessibility, the development of an alternative method with high accuracy is warranted. Our vision is to complement US with additional quantitative imaging information of microvascular morphology that is relevant to disease progression. We propose to develop a new type of imaging biomarkers, based on visualization and quantification of microvasculature morphology without using contrast agents, called “Label- free Ultrasound Angio-Morphometry Analysis ((LUAMA)” to provide complementary diagnostic and prognostic information to conventional US. The goal of this research is to translate the new tool, LUAMA, as a clinical tool for assessment of breast masses. This technology is based on novel processing and quantification procedures to reveal and quantify microvasculature morphology using high frame rate ultrasound imaging. An advantage of this technique is that it does not require the use of contrast agents to produce high-resolution images of the microvasculature. We plan to address two aspects of breast cancer: identifying malignant masses and assessing preoperative chemotherapy response using 3D imaging system for a more accurate estimation of microvessel morphology. The project includes 2 specific aims: (1) Determine the diagnostic performance of LUAMA in a population of pre-biopsy patients with suspicious breast masses, correlate LUAMA results with pathology as the gold standard. (2) Assess and predict the response to preoperative chemotherapy in breast cancer patients using LUAMA and compare the results to MRI as control. This proposal is the result of collaboration among several experts in the field and benefits from the world-class clinical research and facilities at the Mayo Clinic. Successful completion of this research will open the door for a new technology for breast cancer patients in clinic. LUAMA is non-invasive, low cost, easy to use, and compatible with current US technology, which means that this technology can be readily translated to clinic and become available to a wide range of breast patients. Consequently, this research has potential to provide significant impact in breast cancer diagnosis and reducing unnecessary biopsies, as well as assessing response to preoperative chemotherapy.

概括 乳腺肿块的活检前评估是选择合适活检组的非常关键的一步。 当前的成像方法，例如乳房X线照相术和超声（美国），特异性率较低，导致 在美国，不必要的活组织检查的成本很高。 每年损失超过 30 亿美元，并因此给患者带来严重的创伤和焦虑 另一个不确定的领域是评估对术前化疗的反应，其中 MRI 由于价格高且难以获取而具有局限性，因此开发一种具有高成本的替代方法 准确性是有保证的。 我们的愿景是通过额外的微血管形态定量成像信息来补充超声 我们建议开发一种新型的成像生物标志物，基于 不使用造影剂的微血管形态的可视化和量化，称为“Label- 免费超声血管形态测量分析 ((LUAMA)”，提供补充诊断和 这项研究的目标是将新工具 LUAMA 转化为传统美国的预后信息。 用于评估乳房肿块的临床工具该技术基于新颖的处理和量化。 使用高帧率超声成像揭示和量化微血管形态的程序。 该技术的优点是不需要使用造影剂来产生高分辨率 我们计划解决乳腺癌的两个方面：识别恶性。 使用 3D 成像系统评估肿块并评估术前化疗反应，以获得更准确的结果 该项目包括 2 个具体目标：(1) 确定诊断。 LUAMA 在具有可疑乳腺肿块的活检前患者群体中的表现，将 LUAMA 关联起来 (2)评估和预测术前反应 使用 LUAMA 对乳腺癌患者进行化疗，并将结果与​​作为对照的 MRI 进行比较。 该提案是该领域几位专家合作的结果，并受益于世界一流的 梅奥诊所的临床研究和设施的成功完成将为这项研究打开大门。 LUAMA是一种针对临床乳腺癌患者的新技术，具有无创、成本低、易于使用等特点。 与美国现有技术兼容，这意味着该技术可以很容易地转化为临床和 可供广泛测试的乳腺患者使用，这项研究有潜力提供。 对乳腺癌诊断和减少不必要的活检以及评估产生重大影响 对术前化疗的反应。